{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.588","value":"1.26"},{"groupId":"OG001","spread":"0.444","value":"1.70"},{"groupId":"OG002","spread":"0.684","value":"1.84"},{"groupId":"OG003","spread":"0.346","value":"0.66"},{"groupId":"OG004","spread":"0.970","value":"1.22"},{"groupId":"OG005","spread":"0.737","value":"1.66"},{"groupId":"OG006","spread":"0.509","value":"2.14"},{"groupId":"OG007","spread":"0.982","value":"1.75"},{"groupId":"OG008","spread":"0.769","value":"1.74"},{"groupId":"OG009","spread":"0.562","value":"1.46"},{"groupId":"OG010","spread":"0.404","value":"1.42"},{"groupId":"OG011","spread":"0.494","value":"1.52"},{"groupId":"OG012","spread":"0.753","value":"1.95"},{"groupId":"OG013","spread":"0.460","value":"1.31"},{"groupId":"OG014","spread":"0.733","value":"2.09"},{"groupId":"OG015","spread":"0.587","value":"1.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"27"},{"groupId":"OG009","value":"29"},{"groupId":"OG010","value":"27"},{"groupId":"OG011","value":"63"},{"groupId":"OG012","value":"30"},{"groupId":"OG013","value":"30"},{"groupId":"OG014","value":"26"},{"groupId":"OG015","value":"10"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG006","spread":"0.696","value":"3.65"},{"groupId":"OG008","spread":"1.602","value":"2.83"},{"groupId":"OG009","spread":"1.290","value":"3.52"},{"groupId":"OG010","spread":"1.128","value":"2.63"},{"groupId":"OG011","spread":"0.694","value":"2.32"},{"groupId":"OG012","spread":"1.307","value":"2.69"},{"groupId":"OG013","spread":"2.120","value":"2.67"},{"groupId":"OG014","spread":"2.058","value":"4.69"},{"groupId":"OG015","spread":"1.126","value":"4.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"8"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"8"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"4"}],"units":"Participants"}],"title":"Cycle 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"27"},{"groupId":"OG009","value":"29"},{"groupId":"OG010","value":"27"},{"groupId":"OG011","value":"63"},{"groupId":"OG012","value":"30"},{"groupId":"OG013","value":"30"},{"groupId":"OG014","value":"26"},{"groupId":"OG015","value":"10"}],"units":"Participants"}],"description":"Cabiralizumab serum concentration was determined using a validated enzyme-linked immunosorbent assay (ELISA) method.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with any solid tumor received 2 mg/kg cabiralizumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG000","title":"Cabiralizumab 2 mg/kg Q2W"},{"description":"Participants with any solid tumor received 4 mg/kg cabiralizumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG001","title":"Cabiralizumab 4 mg/kg Q2W"},{"description":"Participants with any solid tumor received 6 mg/kg cabiralizumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG002","title":"Cabiralizumab 6 mg/kg Q2W"},{"description":"Participants with any solid tumor received 1 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG003","title":"Cabiralizumab 1 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants with any solid tumor received 2 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG004","title":"Cabiralizumab 2 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants with any solid tumor received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG005","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants with any solid tumor received 6 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG006","title":"Cabiralizumab 6 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants with any solid tumor received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q3W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG007","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q3W"},{"description":"Participants with NSCLC with no prior exposure to any PD-1 pathway targeting drug (PD-1 naïve) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG008","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Naïve)"},{"description":"Participants with NSCLC with de novo or acquired resistance to an anti-PD-1 targeting drug (PD-1 resistant) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG009","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Resistant)"},{"description":"Participants with SCCHN received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG010","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: SCCHN"},{"description":"Participants with pancreatic cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG011","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Pancreatic Cancer"},{"description":"Participants with advanced ovarian cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG012","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Ovarian Cancer"},{"description":"Participants with RCC received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG013","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: RCC"},{"description":"Participants with malignant glioma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG014","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: GBM"},{"description":"Participants with melanoma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG015","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Melanoma"}],"paramType":"MEAN","populationDescription":"The PK evaluable population included participants who received at least 1 dose of cabiralizumab, had at least 1 available serum concentration data, and adequate PK assessments which could be used to reliably derive at least 1 PK parameter. Not all participants completed 8 cycles.\n\nPK data are reported by treatment regimen for Phase 1a participants and by disease type for Phase 1b participants.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 8, Day 1 predose, and at 0.25, 4, 24, 72, 168, and 336 hours after the end of infusion.","title":"Pharmacokinetics (PK) of Cabiralizumab: Area Under the Concentration Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Normalized by Dose (Phase 1a and 1b)","type":"SECONDARY","unitOfMeasure":"days*µg/mL/mg"}